articles details

On April 12, 2025, Beijing TianTan Hospital, affiliated with Capital Medical University, announced the establishment of the TianTan Center for Rare Neurological Diseases Clinical and Translational Research at the 2025 Neurology Center Annual Conference. Strategic cooperation agreements were signed with three leading institutions, including the Beijing Brain Science and Technology Research Institute and Darwin Biotech. This significant move represents a crucial step in the full - chain innovation of "clinical practice - research - industry" in China's neurological disease field, with a landmark significance and brings new hope to numerous patients with rare neurological diseases.

Though rare in name, rare neurological diseases affect tens of millions of families worldwide. In China, a populous country, there are over 20 million rare disease patients, nearly a third of whom suffer from rare neurological diseases. Diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, neuromyelitis optica, spinal muscular atrophy, and spinocerebellar ataxia inflict great suffering on patients and plunge countless families into困境. With fewer than 100 specialized doctors for rare neurological diseases in China, the doctor - to - patient ratio has a缺口 of over one hundred times, leaving many patients unable to get a confirmed diagnosis despite seeking medical help across different places.

Leveraging the resource advantages of the National Center for Neurological Medicine and integrating its 45 - year accumulation in neurology development, TianTan Hospital established the Center for Rare Neurological Diseases Clinical and Translational Research. It has built an innovative system integrating clinical diagnosis and treatment, experimental research, and industrial transformation with the goals of shortening the diagnostic cycle, breaking through treatment bottlenecks, and accelerating innovative transformation, all aimed at tackling rare disease diagnosis and treatment challenges and bringing hope to patients.

Among the three strategic partners, Beijing Darwin Cell Biotechnology Co., Ltd., a co - builder of the National Neurological Center's ALS and Neurological Repair Joint Laboratory, has already initiated clinical research on multiple rare neurological diseases based on the joint laboratory's translational achievements. Preliminary data shows that these achievements may offer new hope to patients with rare neurological diseases. This represents a major medical breakthrough and a demonstration of humanitarian care for the rare disease community. It highlights China's determination and responsibility in the field of neurological disease diagnosis and treatment and contributes Chinese wisdom and solutions to global neurological disease management. We believe that as the center continues to develop and innovate, more patients will find hope here, with the light of life illuminating the path forward.

‍